Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics, Inc. is a biotechnology company that historically focused on developing long-acting treatments for diseases of the nose and sinuses. The company used its proprietary MATRIX drug-delivery platform to design nasal inserts intended to provide continuous, localized drug delivery while reducing the need for repeated sprays or surgical procedures.

Lyra’s lead investigational programs included LYR-210, a mometasone furoate nasal insert developed for chronic rhinosinusitis without nasal polyps, and LYR-220, a related product candidate developed for chronic rhinosinusitis in patients with nasal polyps. These treatments were evaluated in clinical trials, but the company did not have an approved commercial product based on the available historical information.

Founded in 2005 and based in Waltham, Massachusetts, Lyra conducted its research and development activities primarily in the United States. The company later undertook strategic and operational changes as it evaluated its clinical programs and financing options. Information about its current operating status and leadership may be limited following those changes.

Key Stats

• Today's Range: $0.14 to $0.19
• 50-Day Range: $0.00 to $0.50
• 52-Week Range: $0.00 to $8.75
• Volume: 317 shs
• Average Volume: 499 shs
• Market Capitalization: $336.30 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Lyra Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lyra Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.29% of the float of Lyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 15.11, which indicates bearish sentiment.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 0.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.25% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 10/05/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:LYRA
• Previous Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 27
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $400 thousand
• Price / Sales: 0.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.04) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 1,770,000
• Free Float: 1,717,000
• Market Cap: $336.30 thousand
• Optionable: No Data
• Beta: 0.50